<DOC>
	<DOCNO>NCT00002928</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness paclitaxel treat patient recurrent progressive advanced epithelial ovarian cancer follow previous paclitaxel .</brief_summary>
	<brief_title>Paclitaxel Treating Patients With Recurrent Progressive Advanced Ovarian Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate activity paclitaxel administer weekly schedule patient advanced ovarian cancer fail paclitaxel 3 24 hour infusion schedule . II . Evaluate toxic effect paclitaxel administered weekly schedule patient population . III . Correlate response quality life outcome , include symptom distress , performance status , global quality life . OUTLINE : This single center , open label study . Paclitaxel administer intravenously every week 1 hour infusion . Patients receive prophylactic anti-allergy premedication prior paclitaxel . PROJECTED ACCRUAL : 25-30 patient accrue per year .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent progressive epithelial ovarian cancer define : A serial rise CA 125 minimum 3 sample level great 50 % upper limit normal OR Measurable evaluable disease Disease progression follow paclitaxel give 3 24 hour infusion within past 6 month PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky least 60 % Life expectancy : Not specify Hematopoietic : AGC least 1500/uL Platelet count least 100,000/uL Hepatic : Bilirubin great 1.5 mg/dL Renal : Creatinine great 2.0 mg/dL Other : No active uncontrolled infection No history grade 34 peripheral neuropathy etiology No previously develop severe hypersensitivity reaction paclitaxel Not pregnant lactate Patients childbearing potential must use effective method contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Prior platinum base chemotherapy require Complete recovery myelosuppressive effect prior chemotherapy minimum 3 week At least one prior regimen paclitaxel 3 24 hour infusion within 6 month prior study , intervene chemotherapy Endocrine therapy : No hormone therapy within 3 week entry onto protocol Radiotherapy : No prior radiation therapy major bone marrow are within 4 week entry onto protocol Surgery : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
</DOC>